靶向B细胞成熟抗原的抗体-药物偶联物治疗复发/难治性多发性骨髓瘤的研究进展

国际输血及血液学杂志 Pub Date : 2019-09-20 DOI:10.3760/CMA.J.ISSN.1673-419X.2019.05.013

Yao Chao, Yanping Ma

{"title":"靶向B细胞成熟抗原的抗体-药物偶联物治疗复发/难治性多发性骨髓瘤的研究进展","authors":"Yao Chao, Yanping Ma","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.013","DOIUrl":null,"url":null,"abstract":"Multiple myeloma (MM) is one of the most common types of malignant plasmacytosis. At present, most MM patients still cannot be cured. With rapid development of immunotherapy based on hematological malignancies, the use of antibody-drug conjugate (ADC) GSK2857916 has become a new research hot spot in the treatment of relapsed/refractory multiple myeloma (RRMM). GSK2857916 specifically binds to target cell surface through monoclonal antibodies of B cell maturation antigen (BCMA). Then GSK2857916 is rapidly internalized by the target cell, and plays the role of killing MM cells by releasing the active drug mcMMAF. GSK2857916 is one of the promising immunotherapies for the treatment of RRMM. It has high safety and significant clinical efficacy in the treatment of RRMM patients. This article reviews advances in the study of ADC targeting BCMA in the treatment of RRMM, in order to evaluate the safety and tolerance of GSK2857916 monotherapy for RRMM, and further improve the efficacy and prognosis of patients with RRMM. \n \n \nKey words: \nMultiple myeloma; B-cell maturation antigen; Recurrence; Clinical trial; GSK2857916","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"441-445"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress of antibody-drug conjugate targeting B cell maturation antigen in treatment of relapsed/refractory multiple myeloma\",\"authors\":\"Yao Chao, Yanping Ma\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.05.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Multiple myeloma (MM) is one of the most common types of malignant plasmacytosis. At present, most MM patients still cannot be cured. With rapid development of immunotherapy based on hematological malignancies, the use of antibody-drug conjugate (ADC) GSK2857916 has become a new research hot spot in the treatment of relapsed/refractory multiple myeloma (RRMM). GSK2857916 specifically binds to target cell surface through monoclonal antibodies of B cell maturation antigen (BCMA). Then GSK2857916 is rapidly internalized by the target cell, and plays the role of killing MM cells by releasing the active drug mcMMAF. GSK2857916 is one of the promising immunotherapies for the treatment of RRMM. It has high safety and significant clinical efficacy in the treatment of RRMM patients. This article reviews advances in the study of ADC targeting BCMA in the treatment of RRMM, in order to evaluate the safety and tolerance of GSK2857916 monotherapy for RRMM, and further improve the efficacy and prognosis of patients with RRMM. \\n \\n \\nKey words: \\nMultiple myeloma; B-cell maturation antigen; Recurrence; Clinical trial; GSK2857916\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"441-445\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

多发性骨髓瘤(MM)是恶性浆细胞病最常见的类型之一。目前，大多数MM患者仍无法治愈。随着基于血液系统恶性肿瘤的免疫治疗的快速发展，使用抗体-药物偶合物(ADC) GSK2857916治疗复发/难治性多发性骨髓瘤(RRMM)已成为新的研究热点。GSK2857916通过B细胞成熟抗原(BCMA)单克隆抗体特异性结合靶细胞表面。然后GSK2857916被靶细胞迅速内化，并通过释放活性药物mcMMAF发挥杀伤MM细胞的作用。GSK2857916是一种很有前景的治疗RRMM的免疫疗法。在治疗RRMM患者中安全性高，临床疗效显著。本文综述ADC靶向BCMA治疗RRMM的研究进展，以评价GSK2857916单药治疗RRMM的安全性和耐受性，进一步改善RRMM患者的疗效和预后。关键词:多发性骨髓瘤;b细胞成熟抗原;复发;临床试验;GSK2857916

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Research progress of antibody-drug conjugate targeting B cell maturation antigen in treatment of relapsed/refractory multiple myeloma

Multiple myeloma (MM) is one of the most common types of malignant plasmacytosis. At present, most MM patients still cannot be cured. With rapid development of immunotherapy based on hematological malignancies, the use of antibody-drug conjugate (ADC) GSK2857916 has become a new research hot spot in the treatment of relapsed/refractory multiple myeloma (RRMM). GSK2857916 specifically binds to target cell surface through monoclonal antibodies of B cell maturation antigen (BCMA). Then GSK2857916 is rapidly internalized by the target cell, and plays the role of killing MM cells by releasing the active drug mcMMAF. GSK2857916 is one of the promising immunotherapies for the treatment of RRMM. It has high safety and significant clinical efficacy in the treatment of RRMM patients. This article reviews advances in the study of ADC targeting BCMA in the treatment of RRMM, in order to evaluate the safety and tolerance of GSK2857916 monotherapy for RRMM, and further improve the efficacy and prognosis of patients with RRMM. Key words: Multiple myeloma; B-cell maturation antigen; Recurrence; Clinical trial; GSK2857916

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

国际输血及血液学杂志

自引率

0.00%

发文量

10610

期刊介绍： The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.